Murat Yaşar TAŞ

Murat Yaşar TAŞ

Auto-generated profile, based on publicly available information

Murat Yaşar TAŞ

Nephrology Clinics, Başakşehir Çam and Sakura City Hospital, İstanbul, Türkiye

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2019 in Turkish Journal of Gastroenterology
Verified
Journal Article
Open access
YTYaşar Murat Taş
Yaşar Murat Taş
GHGozde Dervis Hakim
Gozde Dervis Hakim
PKPembe Keskinoğlu
Pembe Keskinoğlu
GKGökçe Kenar
Gökçe Kenar
HYHandan Yarkan
Handan Yarkan
MAMesut Akarsu
Mesut Akarsu
Background/Aims: To translate the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract (UCLA SCTC GIT) 2.0 questionnaire from English to Turkish and to validate it. Materials and Methods: UCLA SCTC GIT 2.0 was translated into Turkish using the translation-retranslation method. The available Turkish GIT 2.0 and the Short Form 36 (SF-36) were administered to 97 Turkish-speaking patients with systemic sclerosis (Ssc). Internal consistency reliability and structural validity were assessed by analyzing the correlations between the UCLA SCTC GIT 2.0 and the SF-36 scales. Internal consistency was determined by calculating Cronbach’s alpha. For evaluation of reliability, the questionnaire scale was repeatedly applied to a subgroup of patients with a 2-week interval, and the intraclass correlation coefficient (ICC) was calculated. The Spearman’s correlation coefficients between the GIT and the SF-36 scores were calculated. Results: A group of 97 patients with Ssc with a mean age of 55.37±11.35 years and a female predominance (87.6%) were included in the study. The Cronbach’s alpha value for the UCLA SCTC GIT 2.0 scale was 0.894. ICC was 0.821 (p=0.000). The scale showed acceptable reliability, with the exception of the diarrhea subscale (alpha=0.356). There was a moderate correlation between the total GIT score and the Short Form 36 (SF-36) subscales. All of the items in the scale were included in the validity analysis owing to their reliability. Conclusion: The Turkish GIT 2.0 scale showed good internal consistency, high reliability, and an acceptable validity. Cite this article as: Taş YM, Derviş Hakim G, Keskinoğlu P, et al. The validity and reliability study of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract (UCLA SCTC GIT) 2.0 questionnaire for the Turkish society. Turk J Gastroenterol 2019; 30(3): 234-41.

24 February 2026 in Turkish Journal of Nephrology
Verified
Journal Article
Open access
PDF file
MTMurat Yaşar Taş
Murat Yaşar Taş
BDBelda Dursun
Belda Dursun
Cite this article as: Taş MY, Dursun B. Association between type 2 diabetes mellitus and multiple myeloma might be a cause of high mortality. Turk J Nephrol. Published online February 23, 2026. doi: 10.5152/turkjnephrol.2026.251246.

28 December 2022 in Cukurova Medical Journal
Verified
Journal Article
Open access
PDF file
AÜAlmıla ÜYÜK
Almıla ÜYÜK
MTMurat Yaşar TAŞ
Murat Yaşar TAŞ
BDBelda Dursun
Belda Dursun
FUFurkan Ufuk
Furkan Ufuk
We present a case of idiopathic membranous glomerulonephritis that presented with venous thromboembolism and was successfully managed with corticosteroid, cyclosporin, appropriate anticoagulant therapy. A 59-year old male patient was referred to our nephrology department who had an outpatient history of swelling in the feet and flank pain was detected proteinuria and thrombosis in the inferior vena cava. Warfarin sodium treatment was started when thrombus was detected in the femoral vein, renal vein and inferior vena cava in the imaging. The patient had 12 g/day proteinuria, hypoalbuminemia, hyperlipidemia and antiphospholipase A2 receptor antibody positivity and treatment was started with the diagnosis of idiopathic membranous nephropathy. The patient who was discharged with oral steroid, cyclosporine and warfarin sodium, but warfarin sodium was changed to rivaroxaban in another clinic due to incompatibility problems, was presented again with dsypnea. Pulmonary embolism was detected. Rivaroxaban was discontinued and low molecular weight heparin treatment was started. There was a very high risk of morbidity and mortality and with appropriate treatment, clinical status and renal function were stabilized. In conclusion, although thromboembolism can be seen in nephrotic syndrome, it may rarely be encountered as the first presentation of nephrotic syndrome. This situation should not be overlooked, appropriate treatments should be provided without delay.